Influence Factors of Pancreatic Cancer: Analysis of 71 Cases_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 TIANMing ^1,2 , MENGWen-bo ¹ , ZHAGNLei ¹ , ZHANGHui ¹ , WANGZheng-feng ¹ , ZHUXiao-liang ¹ , ZHUKe-xiang ¹ , LIXun ¹ ,  ZHOUWen-ce ^1,2

1. The Second Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou 730000, Gansu Province, China;
2. The First Clinical Medical School of Lanzhou University, Lanzhou 730000, Gansu Province, China;

Corresponding?author：

ZHOUWen-ce, Email: zhouwc129@163.com

Keywords：

Pancreatic cancer; Prognosis; Influence factor

DOI：

10.7507/1007-9424.20150277

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the prognostic factors of pancreatic cancer. Methods Clinical data of 71 patients of pancreatic cancer who treated in The First Hospital of Lanzhou University from January 2010 to December 2014 were retrospectively collected to analyze the prognostic factors of pancreatic cancer. Results Sixty patients of the 71 patients were followed up for 5-36 months, with the median time of 16 months, and the 1, 2, and 3-year cumulative survival rates were 60.6%, 23.9%, and 1.4% respectively. Univariate analysis results showed that, gender (P=0.043), lymph node metastasis (P=0.002), distant metastasis (P=0.000), TNM staging (P=0.000), and peripancreatic invasion (P=0.000) were correlated with the prognosis of pancreatic cancer, that female patients, patients with the presence of lymph node metastasis, distant metastasis, later TNM staging, and peripancreatic invasion had worse prognosis. Cox proportional hazard model results showed that, distant metastasis (P=0.047), TNM staging (P=0.002), and peripancreatic invasion (P=0.016) were prognostic factors of pancreatic cancer, patients with the presence of distant metastasis, later TNM staging, and peripancreatic invasion had poor prognosis. Conclusion Distant metastasis, TNM staging, and peripancreatic invasion were independent prognostic factors of pancreatic cancer.

Citation： TIANMing, MENGWen-bo, ZHAGNLei, ZHANGHui, WANGZheng-feng, ZHUXiao-liang, ZHUKe-xiang, LIXun, ZHOUWen-ce. Influence Factors of Pancreatic Cancer: Analysis of 71 Cases. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(9): 1057-1061. doi: 10.7507/1007-9424.20150277 Copy

1.	?Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin, 2015, 65(1):5-29.
2.	Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System:report from the National Cancer Database. Cancer, 2007, 110(4):738-744.
3.	Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system, fourth edition. Lyon:LARC Press, 2010:279-337.
4.	Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York:Springer, 2010:241-249.
5.	Paiella S, De Pastena M, Esposito A, et al. Selective agenesis of pancreatic isthmus parenchyma with preservation of main pancreatic duct continuity, a very rare entity:case report. Int J Surg Case Rep, 2015, 6C:169-171.
6.	Xiao J, Peng F, Yu C, et al. MicroRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Int J Clin Exp Pathol, 2014, 7(11):7442-7450.
7.	Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP, 2010, 11(3):203-212.
8.	Herreros-Villanueva M, Gironella M, Castells A, et al. Molecular markers in pancreatic cancer diagnosis. Clin Chim Acta, 2013, 418:22-29.
9.	劉子文, 趙玉沛. 2011版《NCCN胰腺癌臨床實踐指南》中若干問題的探討. 臨床肝膽病雜志, 2011, 27(11):1131-1134.
10.	Hidalgo M. Pancreatic cancer. N Engl J Med, 2010, 362(17):1605-1617.
11.	于琦, 趙平, 王成鋒. 胰腺癌預后相關因素分析. 中國臨床醫生, 2014, 42(3):23-26.
12.	洪國斌, 周經興, 梁碧玲. 影響中晚期胰腺癌預后因素的Cox回歸分析. 循證醫學, 2006, 6(3):164-166.
13.	馬少軍, 孔棣. 胰腺癌預后相關因素的分析研究. 中國中西醫結合外科雜志, 2014, 20(1):11-16.
14.	戴月娣, 張德祥, 袁蘇徐, 等. 胰腺癌治療方式評價及預后分析. 中國癌癥雜志, 2011, 21(3):211-215.
15.	李文英, 張曉峰, 曹淑紅, 等. 胰腺癌手術患者115例的預后分析. 中國老年學雜志, 2011, 31(15):2867-2869.
16.	李學彥, 郭曉鐘, 李宏宇, 等. 腫瘤標志物檢測在胰腺癌診斷和預后評估中的價值研究. 中國實用內科雜志, 2014, 34(5):499-503.
17.	郭石, 艾福錄. 胰腺癌手術治療預后因素分析. 中華普外科手術學雜志:電子版, 2012, 6(3):301-306.
18.	潘巖, 劉魯明, 陳震, 等. 中西醫結合治療190例老年胰腺癌的預后分析. 臨床肝膽病雜志, 2014, 30(4):330-334.
19.	Kwak BJ, Kim SC, Song KB, et al. Prognostic factors associated with early mortality after surgical resection for pancreatic adenocar-cinoma. Korean J Hepatobiliary Pancreat Surg, 2014, 18(4):138-146.
20.	李詩杰, 胡軍紅, 謝永錚, 等. 根治性切除胰頭癌患者臨床病理資料與預后的關系. 中國普外基礎與臨床雜志, 2014, 21(8):965-970.
21.	周江蛟, 田艷濤, 劉昊, 等. 胰腺癌臨床病理特征與淋巴結轉移的關系. 中華腫瘤雜志, 2013, 35(2):132-134.
22.	魏曉平, 刁暢, 胡明道, 等. 165例胰頭癌的外科治療與預后分析. 腹部外科, 2011, 24(6):355-356.
23.	Li D, Tang H, Hassan MM, et al. Diabetes and risk of pancreatic cancer:a pooled analysis of three large case-control studies. Cancer Causes Control, 2011, 22(2):189-197.
24.	馬娜, 鄧德茂. 64層螺旋CT血管造影結合Ang-2表達評價胰腺癌胰周血管侵犯. 中國CT和MRI雜志, 2014, 12(8):52-54.
25.	趙玉沛. 2011年《NCCN胰腺癌臨床實踐指南》中國版解讀. 中華外科雜志, 2011, 49(9):771-773.

1. ?Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin, 2015, 65(1):5-29.
2. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System:report from the National Cancer Database. Cancer, 2007, 110(4):738-744.
3. Bosman FT, Carneiro F, Hruban RH, et al. WHO classification of tumours of the digestive system, fourth edition. Lyon:LARC Press, 2010:279-337.
4. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York:Springer, 2010:241-249.
5. Paiella S, De Pastena M, Esposito A, et al. Selective agenesis of pancreatic isthmus parenchyma with preservation of main pancreatic duct continuity, a very rare entity:case report. Int J Surg Case Rep, 2015, 6C:169-171.
6. Xiao J, Peng F, Yu C, et al. MicroRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Int J Clin Exp Pathol, 2014, 7(11):7442-7450.
7. Chu D, Kohlmann W, Adler DG. Identification and screening of individuals at increased risk for pancreatic cancer with emphasis on known environmental and genetic factors and hereditary syndromes. JOP, 2010, 11(3):203-212.
8. Herreros-Villanueva M, Gironella M, Castells A, et al. Molecular markers in pancreatic cancer diagnosis. Clin Chim Acta, 2013, 418:22-29.
9. 劉子文, 趙玉沛. 2011版《NCCN胰腺癌臨床實踐指南》中若干問題的探討. 臨床肝膽病雜志, 2011, 27(11):1131-1134.
10. Hidalgo M. Pancreatic cancer. N Engl J Med, 2010, 362(17):1605-1617.
11. 于琦, 趙平, 王成鋒. 胰腺癌預后相關因素分析. 中國臨床醫生, 2014, 42(3):23-26.
12. 洪國斌, 周經興, 梁碧玲. 影響中晚期胰腺癌預后因素的Cox回歸分析. 循證醫學, 2006, 6(3):164-166.
13. 馬少軍, 孔棣. 胰腺癌預后相關因素的分析研究. 中國中西醫結合外科雜志, 2014, 20(1):11-16.
14. 戴月娣, 張德祥, 袁蘇徐, 等. 胰腺癌治療方式評價及預后分析. 中國癌癥雜志, 2011, 21(3):211-215.
15. 李文英, 張曉峰, 曹淑紅, 等. 胰腺癌手術患者115例的預后分析. 中國老年學雜志, 2011, 31(15):2867-2869.
16. 李學彥, 郭曉鐘, 李宏宇, 等. 腫瘤標志物檢測在胰腺癌診斷和預后評估中的價值研究. 中國實用內科雜志, 2014, 34(5):499-503.
17. 郭石, 艾福錄. 胰腺癌手術治療預后因素分析. 中華普外科手術學雜志:電子版, 2012, 6(3):301-306.
18. 潘巖, 劉魯明, 陳震, 等. 中西醫結合治療190例老年胰腺癌的預后分析. 臨床肝膽病雜志, 2014, 30(4):330-334.
19. Kwak BJ, Kim SC, Song KB, et al. Prognostic factors associated with early mortality after surgical resection for pancreatic adenocar-cinoma. Korean J Hepatobiliary Pancreat Surg, 2014, 18(4):138-146.
20. 李詩杰, 胡軍紅, 謝永錚, 等. 根治性切除胰頭癌患者臨床病理資料與預后的關系. 中國普外基礎與臨床雜志, 2014, 21(8):965-970.
21. 周江蛟, 田艷濤, 劉昊, 等. 胰腺癌臨床病理特征與淋巴結轉移的關系. 中華腫瘤雜志, 2013, 35(2):132-134.
22. 魏曉平, 刁暢, 胡明道, 等. 165例胰頭癌的外科治療與預后分析. 腹部外科, 2011, 24(6):355-356.
23. Li D, Tang H, Hassan MM, et al. Diabetes and risk of pancreatic cancer:a pooled analysis of three large case-control studies. Cancer Causes Control, 2011, 22(2):189-197.
24. 馬娜, 鄧德茂. 64層螺旋CT血管造影結合Ang-2表達評價胰腺癌胰周血管侵犯. 中國CT和MRI雜志, 2014, 12(8):52-54.
25. 趙玉沛. 2011年《NCCN胰腺癌臨床實踐指南》中國版解讀. 中華外科雜志, 2011, 49(9):771-773.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Influence Factors of Pancreatic Cancer: Analysis of 71 Cases

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content